Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Evotec SE
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
Results from a Phase II trial have demonstrated the potential of GSK's first-in-class antitubercular agent to be a component of simpler treatment regimens for tuberculosis in the future.
The three companies have joined forces to launch Aurobac Therapeutics, combining their respective strengths to develop a precision approach to treating infections.
Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Bionamics GmbH
- Cyprotex PLC
- DeveloGen AG
- Euprotec Ltd
- Evotec AG
- Evotec BioSystems GmbH
- Evotec Neurosciences GmbH
- Evotec BioSystems AG
- Just Biotherapeutics, Inc.
- Kinaxo Biotechnologies
- Compound Focus
- Just – Evotec Biologics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.